Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Harpoon Therapeutics, Inc. (HARP) since 2019 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Harpoon Therapeutics, Inc.. Table 2 shows the detailed insider transactions. This company's CIK number is 1708493.
Total stock buying since 2019: $516,445,974.
Total stock sales since 2019: $56,506,409.
Total stock option exercises since 2019: $492,629.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2024 | 21,397,205 | $492,135,715 | 0 | $0 | 0 | $0 |
| 2023 | 3,097,000 | $10,000,000 | 0 | $0 | 0 | $0 |
| 2021 | 480,888 | $8,083,426 | 1,654,555 | $33,748,032 | 55,000 | $71,000 |
| 2020 | 15,615 | $195,593 | 455,391 | $9,198,236 | 76,736 | $101,876 |
| 2019 | 431,571 | $6,031,240 | 782,474 | $13,560,141 | 272,329 | $319,753 |
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2024-03 | 21,397,205 | $492,135,715 | 0 | $0 | 0 | $0 |
| 2023-10 | 3,087,000 | $0 | 0 | $0 | 0 | $0 |
| 2023-03 | 10,000 | $10,000,000 | 0 | $0 | 0 | $0 |
| 2021-09 | 10,300 | $83,430 | 0 | $0 | 0 | $0 |
| 2021-07 | 0 | $0 | 10,000 | $140,000 | 10,000 | $6,000 |
| 2021-05 | 0 | $0 | 175,869 | $3,655,253 | 0 | $0 |
| 2021-04 | 0 | $0 | 274,213 | $5,838,191 | 10,000 | $6,000 |
| 2021-02 | 0 | $0 | 394,824 | $7,927,913 | 25,000 | $53,000 |
| 2021-01 | 470,588 | $7,999,996 | 799,649 | $16,186,675 | 10,000 | $6,000 |
| 2020-10 | 0 | $0 | 10,000 | $166,100 | 10,000 | $6,000 |
| 2020-08 | 7,098 | $81,336 | 0 | $0 | 0 | $0 |
| 2020-07 | 1,817 | $19,841 | 10,000 | $161,990 | 10,000 | $6,000 |
| 2020-05 | 0 | $0 | 394,753 | $8,307,140 | 16,098 | $20,827 |
| 2020-04 | 0 | $0 | 8,597 | $106,094 | 8,597 | $16,324 |
| 2020-03 | 0 | $0 | 7,347 | $103,777 | 7,347 | $15,575 |
| 2020-02 | 0 | $0 | 7,347 | $103,819 | 7,347 | $15,575 |
| 2020-01 | 6,700 | $94,416 | 17,347 | $249,316 | 17,347 | $21,575 |
| 2019-12 | 0 | $0 | 734,246 | $12,914,271 | 54,639 | $115,834 |
| 2019-11 | 0 | $0 | 24,078 | $326,112 | 24,078 | $51,045 |
| 2019-10 | 0 | $0 | 24,150 | $319,758 | 24,150 | $51,197 |
| 2019-06 | 0 | $0 | 0 | $0 | 169,462 | $101,677 |
| 2019-05 | 3,000 | $31,246 | 0 | $0 | 0 | $0 |
| 2019-02 | 428,571 | $5,999,994 | 0 | $0 | 0 | $0 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2024-03-11 | Merck Sharp & Dohme Llc | Buy | 21,397,205 | 23.00 | 492,135,715 |
| 2023-10-25 | Lathi Vijay K (10% Owner) | Buy | 1,543,500 | .00 | 0 |
| 2023-10-25 | Hunt Ronald (Director) | Buy | 1,543,500 | .00 | 0 |
| 2023-03-23 | Hunt Ronald (Director) | Buy | 10,000 | 1,000.00 | 10,000,000 |
| 2021-09-22 | Erbez Georgia (Chief Financial Officer) | Buy | 10,300 | 8.10 | 83,430 |
| 2021-07-01 | Wesche Holger (Chief Scientific Officer) | Sale | 10,000 | 14.00 | 140,000 |
| 2021-07-01 | Wesche Holger (Chief Scientific Officer) | Option Ex | 10,000 | .60 | 6,000 |
| 2021-05-27 | Ubs Oncology Impact Fund L.p. (10% Owner) | Sale | 13,961 | 20.26 | 282,849 |
| 2021-05-26 | Ubs Oncology Impact Fund L.p. (10% Owner) | Sale | 3,198 | 20.04 | 64,087 |
| 2021-05-24 | Ubs Oncology Impact Fund L.p. (10% Owner) | Sale | 5,000 | 20.12 | 100,600 |
| 2021-05-21 | Ubs Oncology Impact Fund L.p. (10% Owner) | Sale | 10,907 | 20.21 | 220,430 |
| 2021-05-20 | Ubs Oncology Impact Fund L.p. (10% Owner) | Sale | 11,713 | 20.34 | 238,242 |
| 2021-05-19 | Ubs Oncology Impact Fund L.p. (10% Owner) | Sale | 17,833 | 20.39 | 363,614 |
| 2021-05-18 | Ubs Oncology Impact Fund L.p. (10% Owner) | Sale | 18,402 | 20.67 | 380,369 |
| 2021-05-17 | Ubs Oncology Impact Fund L.p. (10% Owner) | Sale | 4,666 | 20.07 | 93,646 |
| 2021-05-14 | Ubs Oncology Impact Fund L.p. (10% Owner) | Sale | 6,900 | 20.04 | 138,276 |
| 2021-05-13 | Ubs Oncology Impact Fund L.p. (10% Owner) | Sale | 4,855 | 20.06 | 97,391 |
| 2021-05-12 | Ubs Oncology Impact Fund L.p. (10% Owner) | Sale | 29,684 | 20.53 | 609,412 |
| 2021-05-11 | Ubs Oncology Impact Fund L.p. (10% Owner) | Sale | 21,445 | 21.23 | 455,384 |
| 2021-05-10 | Ubs Oncology Impact Fund L.p. (10% Owner) | Sale | 17,133 | 22.12 | 378,981 |
| 2021-05-05 | Ubs Oncology Impact Fund L.p. (10% Owner) | Sale | 10,172 | 22.80 | 231,972 |
| 2021-04-29 | Ubs Oncology Impact Fund L.p. (10% Owner) | Sale | 67,292 | 22.28 | 1,499,265 |
| 2021-04-28 | Ubs Oncology Impact Fund L.p. (10% Owner) | Sale | 51,022 | 21.82 | 1,113,555 |
| 2021-04-27 | Ubs Oncology Impact Fund L.p. (10% Owner) | Sale | 11,829 | 21.12 | 249,887 |
| 2021-04-21 | Ubs Oncology Impact Fund L.p. (10% Owner) | Sale | 8,972 | 19.21 | 172,352 |
| 2021-04-20 | Ubs Oncology Impact Fund L.p. (10% Owner) | Sale | 22,249 | 18.89 | 420,394 |
| 2021-04-19 | Ubs Oncology Impact Fund L.p. (10% Owner) | Sale | 10,056 | 19.68 | 197,952 |
| 2021-04-16 | Ubs Oncology Impact Fund L.p. (10% Owner) | Sale | 5,847 | 20.19 | 118,050 |
| 2021-04-15 | Ubs Oncology Impact Fund L.p. (10% Owner) | Sale | 8,696 | 20.49 | 178,181 |
| 2021-04-15 | Evnin Luke (Other) | Sale | 1,052 | 20.49 | 21,555 |
| 2021-04-14 | Ubs Oncology Impact Fund L.p. (10% Owner) | Sale | 13,806 | 20.45 | 282,263 |
| 2021-04-14 | Evnin Luke (Other) | Sale | 1,671 | 20.45 | 34,163 |
| 2021-04-13 | Ubs Oncology Impact Fund L.p. (10% Owner) | Sale | 16,054 | 19.71 | 316,504 |
| 2021-04-13 | Evnin Luke (Other) | Sale | 1,943 | 19.71 | 38,306 |
| 2021-04-12 | Ubs Oncology Impact Fund L.p. (10% Owner) | Sale | 20,628 | 21.64 | 446,389 |
| 2021-04-12 | Evnin Luke (10% Owner) | Sale | 2,496 | 21.64 | 54,013 |
| 2021-04-09 | Ubs Oncology Impact Fund L.p. (10% Owner) | Sale | 10,300 | 23.67 | 243,801 |
| 2021-04-09 | Evnin Luke (10% Owner) | Sale | 10,300 | 23.67 | 243,801 |
| 2021-04-01 | Wesche Holger (Chief Scientific Officer) | Sale | 10,000 | 20.78 | 207,760 |
| 2021-04-01 | Wesche Holger (Chief Scientific Officer) | Option Ex | 10,000 | .60 | 6,000 |
| 2021-02-17 | Erbez Georgia (Chief Financial Officer) | Option Ex | 25,000 | 2.12 | 53,000 |
| 2021-02-10 | Evnin Luke (10% Owner) | Sale | 183,051 | 20.00 | 3,661,020 |
| 2021-02-09 | Evnin Luke (10% Owner) | Sale | 9,400 | 20.25 | 190,350 |
| 2021-02-08 | Evnin Luke (10% Owner) | Sale | 72,128 | 20.04 | 1,445,445 |
| 2021-02-05 | Evnin Luke (10% Owner) | Sale | 10,172 | 20.01 | 203,541 |
| 2021-02-04 | Evnin Luke (10% Owner) | Sale | 29,730 | 20.37 | 605,600 |
| 2021-02-03 | Evnin Luke (10% Owner) | Sale | 41,922 | 20.21 | 847,243 |
| 2021-02-02 | Evnin Luke (10% Owner) | Sale | 48,421 | 20.13 | 974,714 |
| 2021-01-27 | Evnin Luke (10% Owner) | Sale | 706,825 | 20.00 | 14,136,500 |
| 2021-01-26 | Evnin Luke (10% Owner) | Sale | 1,363 | 21.08 | 28,732 |
| 2021-01-25 | Evnin Luke (10% Owner) | Sale | 13,006 | 21.23 | 276,117 |
| 2021-01-22 | Evnin Luke (10% Owner) | Sale | 24,695 | 21.72 | 536,375 |
| 2021-01-21 | Evnin Luke (10% Owner) | Sale | 26,066 | 22.83 | 595,086 |
| 2021-01-20 | Evnin Luke (10% Owner) | Sale | 17,694 | 24.33 | 430,495 |
| 2021-01-11 | New Leaf Bpo Management Ii, L.l.c (10% Owner) | Buy | 235,294 | 17.00 | 3,999,998 |
| 2021-01-11 | Hunt Ronald (Director) | Buy | 235,294 | 17.00 | 3,999,998 |
| 2021-01-04 | Wesche Holger (Chief Scientific Officer) | Sale | 10,000 | 18.34 | 183,370 |
| 2021-01-04 | Wesche Holger (Chief Scientific Officer) | Option Ex | 10,000 | .60 | 6,000 |
| 2020-10-01 | Wesche Holger (Chief Scientific Officer) | Sale | 10,000 | 16.61 | 166,100 |
| 2020-10-01 | Wesche Holger (Chief Scientific Officer) | Option Ex | 10,000 | .60 | 6,000 |
| 2020-08-19 | Erbez Georgia (Chief Financial Officer) | Buy | 5,000 | 11.40 | 57,000 |
| 2020-08-18 | Erbez Georgia (Chief Financial Officer) | Buy | 2,098 | 11.60 | 24,336 |
| 2020-07-31 | Erbez Georgia (Chief Financial Officer) | Buy | 1,817 | 10.92 | 19,841 |
| 2020-07-01 | Wesche Holger (Chief Scientific Officer) | Sale | 10,000 | 16.20 | 161,990 |
| 2020-07-01 | Wesche Holger (Chief Scientific Officer) | Option Ex | 10,000 | .60 | 6,000 |
| 2020-05-28 | Arix Bioscience Holdings Ltd (10% Owner) | Sale | 366,591 | 21.33 | 7,820,852 |
| 2020-05-27 | Arix Bioscience Holdings Ltd (10% Owner) | Sale | 12,064 | 22.39 | 270,149 |
| 2020-05-18 | Sacks Natalie (Chief Medical Officer) | Sale | 1,522 | 14.77 | 22,478 |
| 2020-05-18 | Sacks Natalie (Chief Medical Officer) | Option Ex | 1,522 | 2.12 | 3,226 |
| 2020-05-12 | Wesche Holger (Chief Scientific Officer) | Sale | 1,400 | 14.09 | 19,720 |
| 2020-05-12 | Wesche Holger (Chief Scientific Officer) | Option Ex | 1,400 | .60 | 840 |
| 2020-05-11 | Wesche Holger (Chief Scientific Officer) | Sale | 1,000 | 14.06 | 14,065 |
| 2020-05-11 | Wesche Holger (Chief Scientific Officer) | Option Ex | 1,000 | .60 | 600 |
| 2020-05-08 | Wesche Holger (Chief Scientific Officer) | Sale | 1,000 | 14.00 | 14,000 |
| 2020-05-08 | Wesche Holger (Chief Scientific Officer) | Option Ex | 1,000 | .60 | 600 |
| 2020-05-07 | Wesche Holger (Chief Scientific Officer) | Sale | 5,350 | 14.13 | 75,574 |
| 2020-05-07 | Wesche Holger (Chief Scientific Officer) | Option Ex | 5,350 | .60 | 3,210 |
| 2020-05-01 | Sacks Natalie (Chief Medical Officer) | Sale | 5,826 | 12.07 | 70,302 |
| 2020-05-01 | Sacks Natalie (Chief Medical Officer) | Option Ex | 5,826 | 2.12 | 12,351 |
| 2020-04-28 | Wesche Holger (Chief Scientific Officer) | Sale | 1,250 | 14.05 | 17,565 |
| 2020-04-28 | Wesche Holger (Chief Scientific Officer) | Option Ex | 1,250 | .60 | 750 |
| 2020-04-17 | Sacks Natalie (Chief Medical Officer) | Sale | 1,021 | 12.08 | 12,330 |
| 2020-04-17 | Sacks Natalie (Chief Medical Officer) | Option Ex | 1,021 | 2.12 | 2,164 |
| 2020-04-16 | Sacks Natalie (Chief Medical Officer) | Sale | 500 | 12.00 | 6,000 |
| 2020-04-16 | Sacks Natalie (Chief Medical Officer) | Option Ex | 500 | 2.12 | 1,060 |
| 2020-04-13 | Sacks Natalie (Chief Medical Officer) | Sale | 4,556 | 12.06 | 54,959 |
| 2020-04-13 | Sacks Natalie (Chief Medical Officer) | Option Ex | 4,556 | 2.12 | 9,658 |
| 2020-04-07 | Sacks Natalie (Chief Medical Officer) | Sale | 570 | 12.00 | 6,840 |
| 2020-04-07 | Sacks Natalie (Chief Medical Officer) | Option Ex | 570 | 2.12 | 1,208 |
| 2020-04-06 | Sacks Natalie (Chief Medical Officer) | Sale | 700 | 12.00 | 8,400 |
| 2020-04-06 | Sacks Natalie (Chief Medical Officer) | Option Ex | 700 | 2.12 | 1,484 |
| 2020-03-17 | Sacks Natalie (Chief Medical Officer) | Sale | 1,520 | 12.00 | 18,240 |
| 2020-03-17 | Sacks Natalie (Chief Medical Officer) | Option Ex | 1,520 | 2.12 | 3,222 |
| 2020-03-16 | Sacks Natalie (Chief Medical Officer) | Sale | 1 | 12.00 | 12 |
| 2020-03-16 | Sacks Natalie (Chief Medical Officer) | Option Ex | 1 | 2.12 | 2 |
| 2020-03-02 | Sacks Natalie (Chief Medical Officer) | Sale | 5,826 | 14.68 | 85,525 |
| 2020-03-02 | Sacks Natalie (Chief Medical Officer) | Option Ex | 5,826 | 2.12 | 12,351 |
| 2020-02-18 | Sacks Natalie (Chief Medical Officer) | Sale | 1,521 | 15.00 | 22,815 |
| 2020-02-18 | Sacks Natalie (Chief Medical Officer) | Option Ex | 1,521 | 2.12 | 3,224 |
| 2020-02-03 | Sacks Natalie (Chief Medical Officer) | Sale | 5,826 | 13.90 | 81,004 |
| 2020-02-03 | Sacks Natalie (Chief Medical Officer) | Option Ex | 5,826 | 2.12 | 12,351 |
| 2020-01-21 | Erbez Georgia (Chief Financial Officer) | Buy | 6,700 | 14.09 | 94,416 |
| 2020-01-16 | Sacks Natalie (Chief Medical Officer) | Sale | 1,521 | 14.94 | 22,725 |
| 2020-01-16 | Sacks Natalie (Chief Medical Officer) | Option Ex | 1,521 | 2.12 | 3,224 |
| 2020-01-02 | Wesche Holger (Chief Scientific Officer) | Sale | 10,000 | 14.40 | 143,990 |
| 2020-01-02 | Wesche Holger (Chief Scientific Officer) | Option Ex | 10,000 | .60 | 6,000 |
| 2020-01-02 | Sacks Natalie (Chief Medical Officer) | Sale | 5,826 | 14.18 | 82,601 |
| 2020-01-02 | Sacks Natalie (Chief Medical Officer) | Option Ex | 5,826 | 2.12 | 12,351 |
| 2019-12-27 | Baeuerle Patrick (Director) | Sale | 87,379 | 16.93 | 1,479,151 |
| 2019-12-17 | Arix Bioscience Holdings Ltd (10% Owner) | Sale | 12,476 | 16.83 | 209,971 |
| 2019-12-17 | Chin Mark (Director) | Sale | 12,476 | 16.83 | 209,971 |
| 2019-12-16 | Arix Bioscience Holdings Ltd (10% Owner) | Sale | 13,080 | 17.02 | 222,686 |
| 2019-12-16 | Chin Mark (Director) | Sale | 13,080 | 17.02 | 222,686 |
| 2019-12-16 | Sacks Natalie (Chief Medical Officer) | Sale | 1,521 | 17.02 | 25,887 |
| 2019-12-16 | Sacks Natalie (Chief Medical Officer) | Option Ex | 1,521 | 2.12 | 3,224 |
| 2019-12-13 | Arix Bioscience Holdings Ltd (10% Owner) | Sale | 11,002 | 17.21 | 189,344 |
| 2019-12-13 | Chin Mark (Director) | Sale | 11,002 | 17.21 | 189,344 |
| 2019-12-10 | Arix Bioscience Holdings Ltd (10% Owner) | Sale | 131,696 | 16.91 | 2,226,979 |
| 2019-12-10 | Chin Mark (Director) | Sale | 131,696 | 16.91 | 2,226,979 |
| 2019-12-09 | Arix Bioscience Holdings Ltd (10% Owner) | Sale | 103,754 | 18.21 | 1,889,049 |
| 2019-12-09 | Chin Mark (Director) | Sale | 103,754 | 18.21 | 1,889,049 |
| 2019-12-06 | Arix Bioscience Holdings Ltd (10% Owner) | Sale | 47,752 | 19.14 | 914,212 |
| 2019-12-06 | Chin Mark (Director) | Sale | 47,752 | 19.14 | 914,212 |
| 2019-12-04 | Erbez Georgia (Chief Financial Officer) | Option Ex | 47,292 | 2.12 | 100,259 |
| 2019-12-02 | Sacks Natalie (Chief Medical Officer) | Sale | 5,826 | 17.98 | 104,751 |
| 2019-12-02 | Sacks Natalie (Chief Medical Officer) | Option Ex | 5,826 | 2.12 | 12,351 |
| 2019-11-18 | Sacks Natalie (Chief Medical Officer) | Sale | 18,252 | 13.66 | 249,413 |
| 2019-11-18 | Sacks Natalie (Chief Medical Officer) | Option Ex | 18,252 | 2.12 | 38,694 |
| 2019-11-01 | Sacks Natalie (Chief Medical Officer) | Sale | 5,826 | 13.16 | 76,699 |
| 2019-11-01 | Sacks Natalie (Chief Medical Officer) | Option Ex | 5,826 | 2.12 | 12,351 |
| 2019-10-15 | Sacks Natalie (Chief Medical Officer) | Sale | 11,698 | 13.21 | 154,483 |
| 2019-10-15 | Sacks Natalie (Chief Medical Officer) | Option Ex | 11,698 | 2.12 | 24,799 |
| 2019-10-14 | Sacks Natalie (Chief Medical Officer) | Sale | 12,452 | 13.27 | 165,275 |
| 2019-10-14 | Sacks Natalie (Chief Medical Officer) | Option Ex | 12,452 | 2.12 | 26,398 |
| 2019-06-05 | Mcmahon Gerald Phd (President and CEO) | Option Ex | 169,462 | .60 | 101,677 |
| 2019-05-14 | Mcmahon Gerald Phd (President and CEO) | Buy | 1,000 | 10.16 | 10,157 |
| 2019-05-08 | Mcmahon Gerald Phd (President and CEO) | Buy | 1,000 | 10.56 | 10,559 |
| 2019-05-03 | Mcmahon Gerald Phd (President and CEO) | Buy | 1,000 | 10.53 | 10,530 |
| 2019-02-12 | Arix Bioscience Holdings Ltd (10% Owner) | Buy | 428,571 | 14.00 | 5,999,994 |
Insider trading activities including stock purchases, stock sales, and option exercises of HARP listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Harpoon Therapeutics, Inc. (symbol HARP, CIK number 1708493) see the Securities and Exchange Commission (SEC) website.